JP2022553813A5 - - Google Patents

Info

Publication number
JP2022553813A5
JP2022553813A5 JP2022525717A JP2022525717A JP2022553813A5 JP 2022553813 A5 JP2022553813 A5 JP 2022553813A5 JP 2022525717 A JP2022525717 A JP 2022525717A JP 2022525717 A JP2022525717 A JP 2022525717A JP 2022553813 A5 JP2022553813 A5 JP 2022553813A5
Authority
JP
Japan
Application number
JP2022525717A
Other languages
Japanese (ja)
Other versions
JP2022553813A (ja
JPWO2021092355A5 (https=
JP7677964B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/059378 external-priority patent/WO2021092355A1/en
Publication of JP2022553813A publication Critical patent/JP2022553813A/ja
Publication of JPWO2021092355A5 publication Critical patent/JPWO2021092355A5/ja
Publication of JP2022553813A5 publication Critical patent/JP2022553813A5/ja
Priority to JP2025076140A priority Critical patent/JP2025118753A/ja
Application granted granted Critical
Publication of JP7677964B2 publication Critical patent/JP7677964B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022525717A 2019-11-08 2020-11-06 ヘテロIgG分子の対合のための電荷対変異の操作 Active JP7677964B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025076140A JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933205P 2019-11-08 2019-11-08
US62/933,205 2019-11-08
PCT/US2020/059378 WO2021092355A1 (en) 2019-11-08 2020-11-06 Engineering charge pair mutations for pairing of hetero-igg molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025076140A Division JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Publications (4)

Publication Number Publication Date
JP2022553813A JP2022553813A (ja) 2022-12-26
JPWO2021092355A5 JPWO2021092355A5 (https=) 2023-11-14
JP2022553813A5 true JP2022553813A5 (https=) 2023-11-14
JP7677964B2 JP7677964B2 (ja) 2025-05-15

Family

ID=73740489

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525717A Active JP7677964B2 (ja) 2019-11-08 2020-11-06 ヘテロIgG分子の対合のための電荷対変異の操作
JP2025076140A Pending JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025076140A Pending JP2025118753A (ja) 2019-11-08 2025-05-01 ヘテロIgG分子の対合のための電荷対変異の操作

Country Status (8)

Country Link
US (1) US20220389119A1 (https=)
EP (2) EP4628498A3 (https=)
JP (2) JP7677964B2 (https=)
AU (1) AU2020380379A1 (https=)
CA (1) CA3160482A1 (https=)
ES (1) ES3040852T3 (https=)
MX (1) MX2022005566A (https=)
WO (1) WO2021092355A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025137454A1 (en) 2023-12-21 2025-06-26 Amgen Inc. Stabilizing homodimer mutations for two cell heterodimer production

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
IN2009DN05758A (https=) 2007-03-12 2015-07-24 Esbatech Ag
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
US20090074780A1 (en) 2007-06-25 2009-03-19 David Urech Methods of modifying antibodies, and modified antibodies with improved functional properties
ES2563027T3 (es) 2008-01-07 2016-03-10 Amgen Inc. Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
US20140038285A1 (en) 2011-03-11 2014-02-06 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
EP2686345B1 (en) * 2011-03-16 2018-04-25 Amgen Inc. Fc variants
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US20190309092A1 (en) * 2016-07-21 2019-10-10 Development Center For Biotechnology Modified antigen-binding fab fragments and antigen-binding molecules comprising the same
DK3661954T3 (da) 2017-08-03 2022-04-19 Amgen Inc Interleukin-21-muteiner og fremgangsmåder til behandling
TW201930344A (zh) * 2018-01-12 2019-08-01 美商安進公司 抗pd-1抗體及治療方法

Similar Documents

Publication Publication Date Title
JP2022553813A5 (https=)
BR102020021699A2 (https=)
CN305818771S (https=)
CN305799379S (https=)
CN305536989S (https=)
CN305536255S (https=)
CN305535905S (https=)
CN305531111S (https=)
CN305529637S (https=)
CN305528760S (https=)
CN305527954S (https=)
CN305527351S (https=)
CN305866266S (https=)
CN305822889S (https=)
CN305821763S (https=)
CN305819220S (https=)
CN305554957S (https=)
CN305818290S (https=)
CN305798663S (https=)
CN305798619S (https=)
CN305796757S (https=)
CN305796195S (https=)
CN305795553S (https=)
CN305794818S (https=)
CN305793539S (https=)